PRESS RELEASE 2022

Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by Phase 3 results demonstrating that more than half of patients (51% of CIS ± Ta/T1 cohort) achieve...

Ferring’s novel first-in-class REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI The safety and efficacy of REBYOTA was studied in the largest clinical trial ...

Parsippany, NJ, USA – November 28, 2022 – Ferring Pharmaceuticals appreciates the continued support from New Jersey and Minnesota as both states recognize November as Clostridioides difficile (C. diff) Infection Awareness Month. This is the third year in a row that the offices of Governor Phil Mu...

Investigational RBX2660 showed statistically significant treatment success at reducing CDI recurrence at eight weeks compared to placebo at eight weeks In the study, RBX2660 was well tolerated with primarily mild-to-moderate AEs and no treatment-related SAEs Recurrent C. difficile infection repre...

A new 24-month subgroup analysis looked at sustained clinical response in participants who received up to two doses of RBX2660 across age, sex, race, and number of prior CDI episodes Two post hoc analyses of RBX2660 reviewed physical, mental, and social health-related quality of life (HRQL) data ...

In collaboration with a multi-disciplinary team of leading experts, FertilityWise offers a convenient, tech-based solution for fertility information. This new offering underscores Ferring’s commitment to helping educate healthcare providers by compiling innovative, evidence-based content related ...

Subgroup analysis of Phase 3 trial (PUNCH™ CD3) looked at health-related quality of life data in patients treated with RBX2660 versus placebo Separate subgroup analysis reviewed efficacy and safety data for RBX2660 across a range of patients including those over age 65 years with recurrent C. dif...

Findings from the analysis underscore Ferring’s commitment to identifying and addressing the needs of healthcare professionals and fertility clinic staff who are helping aspiring parents build their families  Parsippany, NJ – October 19, 2022 – Ferring Pharmaceuticals today announced that it will...

Created in partnership with Robyn, a community-driven digital platform, Fertility Outreach evolves the fertility journey by providing a text-based solution for those seeking information and guidance on their path to parenthood Fertility Outreach exemplifies Ferring’s innovative approach to addres...

Vaccines and Related Biological Products Advisory Committee reviewed data from the biologics license application for RBX2660 RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment Recur...

Ferring to share insights and expertise across a range of timely and critical topics at the Women’s Health Innovation Summit in Boston As the headline sponsor, Ferring will have a significant presence with executives providing the keynote address, participating on several panels and hosting an In...

Vaccines and Related Biological Products Advisory Committee will hold meeting on September 22, 2022 RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection after antibiotic treatment Saint-Prex, Switzerland and Parsip...

New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body of evidence of the RBX2660 clinical development program – the largest, most robust program conducte...

Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI) after antibiotic treatment, as part of Digestive Disease Week (D...

Primary objective was to compare treatment success of RBX2660 to historical control group A key secondary outcome was the safety profile of RBX2660 through 24 months after treatment Post hoc analysis indicated that 91% of evaluable responders remained CDI occurrence-free to 24 months after treatm...

Ferring Pharmaceuticals has finalized a two-year investment agreement including an acquisition option with Robyn. Together, Ferring and Robyn will provide expanded resources for people on their path to parenthood. The investment in Robyn reflects Ferring’s strategy to partner with innovative star...

Ferring’s Microbiome Health Index™ is a promising tool that measures disrupted gut microbiota after antibiotic treatment, subsequent gut microbiota restoration, and the potential clinical impact of microbiome-based live biotherapeutics Parsippany, NJ, USA – January 7, 2022 – Ferring Pharmaceutica...